March 30, 2022

Whom It May Concern
Company:
Representative:Contact:

Telephone:

KYORIN Holdings, Inc.
Yutaka Ogihara
Representative Director, President(Security Code: 4569, TSE 1st Sec.)
Yoshinori Tanifuji
Director, Management Strategy &Planning Division Corporate Planning+81-3-3525-4707

KYORIN and Lumen Bioscience Reach Collaboration Research Agreement
KYORIN Holdings, Inc. today announced that its wholly owned subsidiary of KYORIN
pharmaceutical Co., Ltd. (Head office: Chiyoda-ku, Tokyo, President & CEO: Shigeru Ogihara,“KYORIN Pharmaceutical”) has entered into a collaboration research agreement with Lumen
Bioscience, Inc. (Head office: Seattle, WA, CEO: Brian Finrow, “Lumen”) to obtain a development
candidate toward clinical study.
Under the terms of the agreement, KYORIN Pharmaceutical and Lumen will promote thecollaboration research to obtain a clinical candidate for targets in the disease areas of interest toKyorin Pharmaceutical by utilizing Lumen’s spirulina genetic protein engineering technology.
Biologic drugs (including antibodies) have conventionally been produced from E. coli, yeast, ormammalian cells. Lumen is the first company to establish a scalable method for manufacturing
biologic drugs by genetically engineering spirulina instead of using these conventional methods.
Spirulina, which is a well-known and healthy food product, can solubly express therapeutic proteins
like these at extraordinarily high levels within its cytoplasm. And because both spirulina itself is safeto eat, the entire biomass—including the therapeutic proteins within—can be consumed orally
without the costly and inefficient downstream purification steps required with conventional
approaches. This technology is expected to provide safe orally deliverable biologic drugs at much
lower costs than current approaches.
KYORIN Pharmaceutical believes that this opportunity to collaborate with Lumen’s breakthroughtechnology will enhance our research capabilities.

About Lumen Bioscience, Inc.
Foundation:April 2017
CEO & Chairman: Brian Finrow
Employees:
70 (as of March 31, 2021)
Overview:
Lumen discovers, develops, and manufactures biologic drug candidates forseveral prevalent, worldwide diseases—many of which currently lack any
effective treatments.
The company’s unique drug development andmanufacturing platform offers the potential to transform the biologics industry
through increased speed, mass-market scale, and exponentially lower costs thancurrent approaches. Lumen’s clinical pipeline includes investigational biologic
drugs for C. difficile infection, Covid-19, cardiometabolic disease, inflammatory
bowel disease, norovirus, and traveler’s diarrhea. For more information, visit:www.lumen.bio.
About Lumen’s Spirulina Genetic Modification Technology
Lumen is radically changing previous assumptions about the cost, scale and time at which biologic
drugs such as antibodies can be manufactured by genetically engineering spirulina, a type of bluegreen algae that is cultivated and consumed around the world. Lumen engineers spirulina to serve
as both a low-cost factory and a safe delivery vehicle for antibodies and other protein therapeutics.
No purification of the therapeutic protein is needed for oral delivery; instead, the final drug productis whole, unrefined spirulina biomass containing large amounts of the therapeutic proteins. Thismeans that the cost is just pennies per dose, and the robust safety record of both oral therapeuticproteins and spirulina itself reduces the cost and risk of clinical development.

About KYORIN Pharmaceutical Co., Ltd.
Foundation:
December 1923
President & CEO: Shigeru Ogihara
Annual Sales:
JPY89.674 billion (Fiscal Year ending on March 31, 2021)
Employees:
1,471 (as of March 31, 2021)
Overview:
Trusted among patients and professionals in the medical industry, KYORIN
Pharmaceutical strives to be the pharmaceutical company recognized as aone with social significance by improving its presence in the specifictherapeutic areas and through global discovery of novel drugs. KYORIN
Pharmaceutical uses franchise customer strategy where its marketingefforts are focused on respiratory medicine, otolaryngology and urology. In
drug discovery, it is deploying 'selection and concentration' and promoting
activities aimed at first-in-class drug discovery, such as actively searchingfor and introducing external drug discovery themes as well as multi-tiered
program development.